Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s

ADA 2025: Semaglutide taken orally shown to reduce cardiovascular risk in type 2 diabetes patients - Cardiovascular News

Research presented at the American Diabetes Association (ADA) 2025 scientific session (20–23 June, Chicago, USA) has shown that oral semaglutide offers a cardiovascular benefit for individuals with type 2 diabetes, by lowering their risk for major adverse cardiovascular events (MACE). Semaglutide is typically administered via an injection, but it is thought that delivering the anti-diabetes orally medication may improve adherence and support ear…